NSPRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
InspireMD, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.44−0.02 (-3.34%)
Close on Oct 19, 2026
- Market cap
- $37.25M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2008 to 2025
Gross margin
29.5%+26.2 pts over 5 years
Operating margin
-552.6%−134.8 pts over 5 years
Net margin
-543.3%−119.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +28.1% | +20.2% | +29.3% | +14.5% | |
| Gross profit | +75.9% | +33.4% | +99.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -1539.8% | -120.2% | -106.9% | |
| Return on assets | -112.0% | -76.2% | -84.0% | |
| Current ratio | 1.81 | 4.14 | 5.74 | |
| Interest coverage | -10.6× | – | – | |
| Inventory turnover | 2.9× | 1.8× | 2.1× | |
| Capex to revenue | 2.6% | 3.5% | 18.5% | |
| Diluted shares | 0M | 2M | 64M |
Where the cash went
Fiscal 2021 to 2025, five years combined
InspireMD generated $102.10M from operations and spent $4.26M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$102.10M
Used
$4.26M
Capital expenditure$4.26M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-543.3%
×Asset turnover0.15×
×Equity multiplier1.27×
=Return on equity, FY2025-106.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -543.3% | 0.15× | 1.27× | -106.9% |
| FY2024 | -456.6% | 0.15× | 1.25× | -84.7% |
| FY2023 | -321.0% | 0.17× | 1.27× | -70.0% |
| FY2022 | -357.6% | 0.16× | 1.26× | -72.6% |
| FY2021 | -331.9% | 0.16× | 1.26× | -65.3% |
| FY2020 | -424.3% | 0.18× | 1.58× | -120.2% |
| FY2019 | -269.8% | 0.34× | 1.57× | -141.9% |
| FY2018 | -201.1% | 0.39× | 1.60× | -126.0% |
| FY2017 | -305.6% | 0.36× | 2.29× | -249.2% |
| FY2016 | -446.7% | 0.25× | 13.74× | -1539.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$48.79M
- Cash generatingOperating cash flow above zero-$35.10M
- Return on assets improvedROA up on the prior year-67.2% → -104.2%
- Earnings backed by cashOperating cash flow above net income-$35.10M vs -$48.79M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.28 → 5.74
- No dilutionShare count did not rise42M → 64M
- Gross margin improvedGross margin up on the prior year21.49% → 29.50%
- More efficientAsset turnover rose0.15 → 0.19